Ignite Creation Date:
2024-05-06 @ 8:05 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06243354
Status:
RECRUITING
Last Update Posted:
2024-02-07
First Post:
2024-01-25
Brief Title:
Phase 12 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
Sponsor:
Sichuan Huiyu Pharmaceutical Co Ltd
Organization:
Sichuan Huiyu Pharmaceutical Co Ltd
Study Overview
Official Title:
An Open-label Multi-center Multi-cohort Phase 12 Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of HYP-2090PTSA in Patients With Advanced Solidt Tumors Harboring KRAS Mutation
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open-label phase 12 study consisting of two parts dose escalation phase and dose expansion phase The objective of the dose escalation phase is to evaluate the safety tolerability and pharmacokinetics of HYP-2090PTSA in patients with advanced solid tumors harboring KRAS mutation and to determine the RP2D In the dose expansion phase preliminary efficacy and safety at the RP2D will be further explored in patients with specific cancer harboring KRAS pG12C mutation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None